SAN DIEGO, Oct 26, 2010 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced HiSeq 1000, a single flow cell version of the company's HiSeq 2000 sequencing system. HiSeq 1000 is designed for researchers who want the ease of use, industry-leading cost per gigabase (Gb) and data rate of the HiSeq 2000 but do not currently require its throughput. As their research scales, users will be able to upgrade their system to the HiSeq 2000 and double their output.
"We are thrilled with the market's enthusiasm for our HiSeq 2000 platform, which is enabling sequencing studies on an unprecedented scale. With HiSeq 1000, we're offering researchers an additional entry point into the most powerful and cost-effective sequencing technology available," said Jay Flatley, President and CEO of Illumina. "Powered by TruSeq reagents and leveraging the HiSeq 2000 architecture, HiSeq 1000 will provide researchers who have lower throughput requirements an ideal platform to address their current research demands. As those demands change, users can scale easily through an upgrade to handle future sequencing needs."
HiSeq 1000 relies on the same cutting-edge, dual-surface imaging technology and breakthrough user experience as the HiSeq 2000, offering unmatched cost effectiveness and the easiest-to-use workflow of any sequencing platform. At launch, it is expected HiSeq 1000 will deliver in excess of 100 Gb of data per run using paired 100 base pair reads, easily enabling the sequencing of a complete human genome in a single run. To address the broad range of gene expression and epigenetic applications, HiSeq 1000 can deliver greater than 750 million high-quality single reads per run in as few as two days, providing rapid and cost effective transcriptional profiling, ChIP-SEQ, and methylation mapping.
The company is currently accepting orders for HiSeq 1000 and expects to begin shipping the first systems in the mid to latter part of the first quarter of 2011. For more information, please visit http://www.illumina.com/hiseq1000.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
858-882-6822
wgrabill@illumina.com
